As an Organized Provider Account Lead, I engage with C-suite and population-based decision makers (PBDMs) at major US Health Systems to execute strategies that drive brand growth and improve healthcare. These efforts are focused on improving patient experience, positively impacting population health, and controlling cost of care. I collaborate with GSK cross-functional stakeholders to improve engagement in selected strategic accounts, including working closely with my Field Medical Account… Show more As an Organized Provider Account Lead, I engage with C-suite and population-based decision makers (PBDMs) at major US Health Systems to execute strategies that drive brand growth and improve healthcare. These efforts are focused on improving patient experience, positively impacting population health, and controlling cost of care. I collaborate with GSK cross-functional stakeholders to improve engagement in selected strategic accounts, including working closely with my Field Medical Account Leads to deliver a customer-centric, cross-functional account plan that compliantly addresses both commercial and medical objectives. I work with strategic marketers to develop a customer needs assessment, identify, and deliver commercial value propositions while bringing voice of customer into GSK to build strategies, including contracts and resources. Show less

As Head of Strategic Accounts, Oncology East I led a team of strategic account directors supporting c-suite and director level leadership at the largest oncology practices in the eastern half of the United States. This team ensures the complete and accurate integration of GSK oncology products into the systems and platforms used to standardize care, identifying innovative engagement opportunities, supporting contract pull through and leading commercial field matrix team planning at… Show more As Head of Strategic Accounts, Oncology East I led a team of strategic account directors supporting c-suite and director level leadership at the largest oncology practices in the eastern half of the United States. This team ensures the complete and accurate integration of GSK oncology products into the systems and platforms used to standardize care, identifying innovative engagement opportunities, supporting contract pull through and leading commercial field matrix team planning at accounts.• Established strong working relationship with executive level leadership at high volume, high control, sophisticated oncology practices in community, academic and integrated delivery network settings. • Executed three launches in 2023, including leading the team through the execution of Pre-Investigational Exchange discussions with appropriate customers, the roll-out of specialty GPO contracts and the introduction of a new Strategic Account Management model. • Led operations planning for national team, translating brand plans into strategic, tactical and resource plans appropriate for reaching and impacting provider population-based decision makers and platforms. • Developed several workshops and presentations to lead cross functional stakeholders in a deeper understanding of the external payment policy landscape and how this is impacting the development of pathways, formularies and treatment plans at organized accounts. • Launched formal reporting initiative designed to generate validated and nuanced insights regarding account-based provider utilization and clinical decision support platforms to inform strategy and targeting. • Drove cross functional planning and led project teams for account-based commercial data projects with third party vendors and directly with strategic accounts. The efforts addressed data gaps, established new ways of working and informed brand and strategic account strategies and tactics. Show less

As the US Lead for the Lung Ambition Alliance for AstraZeneca (a partnership between AstraZeneca, Guardant, IASLC and GLCC), I was responsible for driving initiatives to double five-year lung cancer survival rates by 2025. I established and aligned priorities, goals, and desired health outcomes, integrated above-brand tactics to define AstraZeneca’s contributions and measure results. Devised approaches to support projects fostering early detection, improved patient access to innovative… Show more As the US Lead for the Lung Ambition Alliance for AstraZeneca (a partnership between AstraZeneca, Guardant, IASLC and GLCC), I was responsible for driving initiatives to double five-year lung cancer survival rates by 2025. I established and aligned priorities, goals, and desired health outcomes, integrated above-brand tactics to define AstraZeneca’s contributions and measure results. Devised approaches to support projects fostering early detection, improved patient access to innovative treatments, and enhanced quality of care leveraging collaborations.• Enhanced awareness and expanded patient advocacy initiatives, utilizing multimedia approaches and networking opportunities to further Lung Ambition Alliance’s mission.• Developed and launched global X (formerly Twitter) account to maximize nationwide outreach.• Mobilized the first USLAA steering committee, recruiting and organizing members across the oncology ecosystem to inform US strategy and accelerate the impact of USLAA tactics. • Conducting presentations, one-on-one meetings, and webinars, including an internal educational series on lung cancer screening.• Developed strong cross-functional partnerships and increased engagement among internal and external stakeholders, including medical, sales, marketing, and corporate leaders. Synergized efforts to target common customer segments.• Engaged key external experts (KEEs) from the U.S. in offering guidance and expertise to national programs.• Facilitated collaborations across stakeholder groups, including American Cancer Society’s National Lung Cancer Roundtable as well as AstraZeneca’s BioPharmaceuticals Business Unit (BBU) and Veterans Affairs team.• Drove innovative pilots and provided subject matter expertise to advance research and establish best practices in lung cancer care, including the use of technology to improve lung cancer identification and biomarker testing optimization. Show less

As a National Oncology Account Director, I led strategic account engagement with oncology accounts’ executive/director-level leadership to advance AstraZeneca Oncology business priorities. I was responsible for portfolio and product value proposition communication, ensuring formulary access, pathway inclusion, GPO pull through and leading innovative initiatives focused on aligned priorities. This included leading account planning for specific accounts and collaborating cross functionally with… Show more As a National Oncology Account Director, I led strategic account engagement with oncology accounts’ executive/director-level leadership to advance AstraZeneca Oncology business priorities. I was responsible for portfolio and product value proposition communication, ensuring formulary access, pathway inclusion, GPO pull through and leading innovative initiatives focused on aligned priorities. This included leading account planning for specific accounts and collaborating cross functionally with AZ team members to ensure effective plan implementation.• Earned 2019 OneKAM Excellence Award for outstanding impact through work with field team to support improved biomarker testing practices and data collection for Tennessee Oncology, a community-based cancer care group.• Accelerated development and implementation of oncology customer programs, fostering brand alignment, and improving processes for budgeting requests and compliance/legal reviews.• Co-led initiative with Duke Cancer Institute to co-develop and research the useability and feasibility of a Digital PRO/Patient Education tool to improve engagement with supportive care services (poster published November 2019).• Created competitive advantage through strategic engagement, management, and planning for priority accounts, working with multidisciplinary internal team to ensure effective plan implementation and availability of key project deliverables, ie. Duke Cancer Network Lung Cancer Screening Initiative, Tennessee Oncology Precision Medicine Project.• Hired, coached and led associate director to optimize impact and customer reach in assigned accounts. Show less

Led a team of 8 individuals in territories across the states of Kentucky, Tennessee, North Carolina and South Carolina. District was ranked among the top in the nation for both Tagrisso and Iressa product launches in lung cancer in 2015. Demonstrating success in leading team with comprehensive account management strategy, biomarker target driven treatment with companion diagnostic, and both highly competitive and first in class markets.

District Manager, responsible for leading 14 representatives across 9 territories covering a large portion of Kentucky and Southern Indiana. Successfully launched 3 products in 2014: Farxiga, the Bydureon Pen and Xigduo XR. Circle of Excellence winner in 2014. Led team through transition from BMS Diabetes Alliance to AstraZeneca.

In this role I mobilized a group of cancer survivors, caregivers, and others interested in fighting lung cancer in a grass roots effort to establish an organization to support lung cancer patients in Kentucky and Indiana. This led to the formal development and launch of the 5th Lung Cancer Alliance in the nation in May of 2010, for which I served as the co-director for five years. • Lead the development of the strategic plan and mobilized the structure and a group of volunteers to… Show more In this role I mobilized a group of cancer survivors, caregivers, and others interested in fighting lung cancer in a grass roots effort to establish an organization to support lung cancer patients in Kentucky and Indiana. This led to the formal development and launch of the 5th Lung Cancer Alliance in the nation in May of 2010, for which I served as the co-director for five years. • Lead the development of the strategic plan and mobilized the structure and a group of volunteers to execute plan. • Drove the inclusion of language on lung cancer screening in the Kentucky State Cancer plan in 2012, leading to a comprehensive organized efforts to address lung cancer as a leading public health issue in Kentucky. As a part of this work, served as the Lung Cancer Screening Task Force Chairperson for the Kentucky Cancer Consortium.• Served as a Community Advisory Board member for the $7 million grant awarded in 2014 to establish the Kentucky LEADS Collaborative (KY Lung Cancer Education Awareness Detection and Survivorship). Since the establishment of this grant, Kentucky’s lung cancer screening rates have grown to 10.6% of eligible patients, double the national average. Show less

Oncology representative focused on the promotion of Erbitux and Sprycel to medical oncologists and other members of the treatment team in geographies stretching from parts of Kentucky, Indiana and West Virginia, with experience as single rep to serving as part of a promotional team.

Specialty oncology representative focused on promoting Erbitux to key medical oncologists and other oncology stakeholders in major university, hospital and community based accounts in Kentucky and Tennessee.

Part-time position on CRYSTAL launch team leading the development of the Breaking Barriers selling tool, serving as liaison to advocacy department for CRYSTAL launch, focusing on advocacy pull-through and consultant to EGFR Specialist strategy and training. Conducted research and completed analysis of advocacy organizations for lung and colon cancer on a national level, identified gaps/opportunities and presented suggested strategies to Bristol-Myers Squibb Oncology advocacy/marketing… Show more Part-time position on CRYSTAL launch team leading the development of the Breaking Barriers selling tool, serving as liaison to advocacy department for CRYSTAL launch, focusing on advocacy pull-through and consultant to EGFR Specialist strategy and training. Conducted research and completed analysis of advocacy organizations for lung and colon cancer on a national level, identified gaps/opportunities and presented suggested strategies to Bristol-Myers Squibb Oncology advocacy/marketing teams—several currently being implemented to maximize advocacy’s reach. Completed similar analysis related to partnerships with national nurse navigator organizations. Project manager for the development and roll out of the Breaking Barriers selling response tool. Leveraging market research insights, field sales experience, and sales leadership feedback. Managing all associated timelines and deliverables. This tool will equip the field sales force to use customer insights to effectively position approved messaging to accelerate growth of CRYSTAL launch. Show less

Promoted Glucophage, Glucophage XR, Pravachol, Avapro/Avalide, Glucovance, and Metaglip in various mixes to primary care physicians, cardiologists and endocrinologists in Southern Indiana and Louisville, Kentucky.

New business development via cold calls and lead follow-up. Managed the sales process from start to finish including proposal generation and presentation, overcoming objections, creating opportunities, and closing the sale. Provided oversight for project execution and assisted in the follow-up and collection if necessary. Expanded depth of customer relationships within the five technology support areas that the company provided.